title: Role of gonadal hormones on mu-opioid-stimulated [³⁵S]GTPγS binding and morphine-mediated antinociception in male and female Sprague-Dawley rats.
abstract: BACKGROUND
  Male rats are more sensitive to morphine-mediated antinociception than female rats. A role for gonadal hormones in this sex difference has not been clearly defined.
  
  
  OBJECTIVE
  To test the hypothesis that in vivo manipulation of gonadal hormones alters morphine-mediated G protein activation and leads to changes in morphine-mediated antinociception.
  
  
  METHODS
  Adult male and female rats were gonadectomized and treated with either estradiol or testosterone in the females or testosterone in the male for up to 10 days. The ability of morphine and the peptidic mu-opioid agonist [D-Ala(2), N-MePhe(4), Gly-ol]-enkephalin (DAMGO) to stimulate [(35)S]GTPγS binding was measured in brain slices. In separate groups of identically treated rats, the antinociceptive response to morphine was determined using the warm-water tail-withdrawal assay.
  
  
  RESULTS
  In the thalamus, morphine- and DAMGO-stimulated [(35)S]GTPγS binding was reduced by estradiol treatment of gonadectomized females compared to gonadectomized females treated with vehicle or testosterone. In the nucleus accumbens, the morphine-stimulated [(35)S]GTPγS binding was increased by estradiol treatment of gonadectomized females. In males, castration caused an increase in agonist-stimulated binding in the thalamus and a reduction in the amygdala compared with intact males. No significant changes were seen in mu-opioid agonist-stimulated [(35)S]GTPγS binding in other brain regions. There was no difference in antinociception following the systemic administration of morphine across the different hormonal manipulation conditions and the greater sensitivity of males was maintained irrespective of the treatment conditions.
  
  
  CONCLUSIONS
  The modulation of mu-opioid receptor activation of G proteins by manipulation of sex hormones is region-specific and not reflected in antinociceptive responsiveness to morphine.
authors: Department of Pharmacology, University of Michigan, Ann Arbor, MI, USA.
authors: Elizabeth M
authors: EM
authors: Peckham
authors: Steven M
authors: SM
authors: Graves
authors: Emily
authors: E
authors: Jutkiewicz
authors: Jill B
authors: JB
authors: Becker
authors: John R
authors: JR
authors: Traynor
references: Am J Physiol. 1992 Sep;263(3 Pt 1):E507-11
references: 1329526
references: Annu Rev Pharmacol Toxicol. 2000;40:389-430
references: 10836142
references: Behav Pharmacol. 1996 Dec;7(8):764-778
references: 11224471
references: Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7242-6
references: 7638174
references: Behav Brain Res. 1999 Jun;101(2):129-52
references: 10372570
references: J Steroid Biochem Mol Biol. 1991;40(1-3):113-21
references: 1659872
references: Brain Res. 1999 Mar 6;821(1):224-30
references: 10064807
references: Clin J Pain. 2003 May-Jun;19(3):175-86
references: 12792556
references: J Neurochem. 2003 Jul;86(2):405-12
references: 12871581
references: J Neurosci. 2003 Jan 15;23(2):693-9
references: 12533629
references: Psychopharmacology (Berl). 2000 Jul;150(4):430-42
references: 10958085
references: J Pharmacol Exp Ther. 1998 May;285(2):496-505
references: 9580589
references: Pain. 1991 Apr;45(1):87-94
references: 1677751
references: J Pharmacol Exp Ther. 1996 Nov;279(2):767-73
references: 8930182
references: Brain Res Mol Brain Res. 1997 Jul;47(1-2):134-8
references: 9221910
references: Psychopharmacology (Berl). 2002 Sep;163(2):183-93
references: 12202965
references: Trends Neurosci. 1988 Jul;11(7):308-14
references: 2465635
references: Neuropsychopharmacology. 2004 Jan;29(1):81-5
references: 12955098
references: Brain Res. 1987 Sep 22;421(1-2):1-13
references: 2825908
references: Endocrinology. 1974 Jun;94(6):1704-8
references: 4857496
references: Pharmacol Biochem Behav. 1989 Sep;34(1):119-27
references: 2626443
references: Behav Brain Res. 2007 Feb 12;177(1):126-33
references: 17118467
references: Brain Res. 2002 Mar 1;929(1):1-9
references: 11852025
references: Brain Res Bull. 2000 Sep 15;53(2):147-52
references: 11044590
references: Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3577-82
references: 11248120
references: Pain. 2003 Dec;106(3):381-391
references: 14659521
references: Eur J Pharmacol. 1996 Jun 20;307(1):97-105
references: 8831110
references: J Neurosci. 1994 Apr;14(4):1978-84
references: 8158252
references: Brain Res Bull. 2003 May 15;60(3):201-8
references: 12754081
references: Brain Res Bull. 1989 Jun;22(6):937-43
references: 2790499
references: Life Sci. 1991;48(21):1991-2003
references: 1851914
references: J Pharmacol Exp Ther. 2006 Mar;316(3):1195-201
references: 16291875
references: Brain Res. 1990 May 7;515(1-2):187-92
references: 2162717
references: Exp Clin Psychopharmacol. 2006 Feb;14(1):1-11
references: 16503700
references: Horm Behav. 2001 May;39(3):216-24
references: 11300712
references: Ann N Y Acad Sci. 1992 Jun 28;654:347-56
references: 1321576
references: Pharmacol Biochem Behav. 2000 Jan 1;65(1):91-6
references: 10638641
references: Brain Res. 2005 Oct 12;1059(1):13-9
references: 16153618
references: J Pharmacol Exp Ther. 2005 Mar;312(3):1314-20
references: 15574687
references: Brain Res Bull. 1997;44(4):327-33
references: 9370196
references: J Pharmacol Exp Ther. 1997 Aug;282(2):939-44
references: 9262361
references: Mol Pharmacol. 1995 Apr;47(4):848-54
references: 7723747
references: Pain. 2003 Jun;103(3):285-302
references: 12791435
references: Brain Res. 2005 Oct 5;1058(1-2):137-47
references: 16139823
references: J Pharmacol Exp Ther. 2002 Feb;300(2):695-701
references: 11805235
references: Eur J Pharmacol. 1983 Dec 23;96(3-4):291-4
references: 6687119